Patents Assigned to Universite Montpellier II
-
Publication number: 20110257120Abstract: This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2?-deoxy-?-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2?-deoxy-?-L-erythro-pentofuranonucleoside has the formula: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2?-deoxy-?-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2?-deoxy-?-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.Type: ApplicationFiled: June 27, 2011Publication date: October 20, 2011Applicants: Idenix Pharmaceuticals, Inc., L'Universite Montpellier II, Centre National de la Recherche ScientifiqueInventors: Gilles Gosselin, Jean-Louis Imbach, Martin L. Bryant
-
Patent number: 8017283Abstract: An electrode for an alkali fuel cell comprises an active layer formed by a bilayer or by a stack of a plurality of bilayers. Each bilayer is composed of a catalytic layer comprising catalyst particles of nanometric size and of a porous layer comprising two opposite faces one of which is in contact with the catalytic layer. The porous layer is made from a porous composite material comprising a hydroxide ion conducting polymer matrix in which a metallic lattice is formed constituting a plurality of electronically conducting paths connecting the two opposite faces of the porous layer. Advantageously, fabrication of such an electrode is obtained by successively performing vacuum deposition of the catalyst particles and vacuum co-deposition of the hydroxide ion conducting polymer and of the metal on a free surface of a support.Type: GrantFiled: October 18, 2006Date of Patent: September 13, 2011Assignees: Commissariat a l'Energie Atomique, Universite Montpellier II, Centre National de la Recherche ScientifiqueInventors: Audrey Martinent, Jean-Yves Laurent, Max Perrin, Mauricio Schieda, Jean Durand, Stephanie Roualdes
-
Patent number: 8017581Abstract: The invention relates to a tripeptide conjugate having general formula I, A-AA1-AA2-AA3-NH2, wherein A represents the radical corresponding to a monocarboxylic acid with general formula II, HOOC—R, in which: R represents a linear or branched aliphatic radical at C1-C24, which is optionally substituted by a hydroxyl group and which can comprise one or more unsaturations, preferably between 1 and 6 unsaturations, lipoic acid or the reduced form thereof, dihydrolipoic acid, N-lipoyllysine, or phenylbutyric acid; and AA1, AA2 and AA3, which may be identical or different, represent independently of each other an amino acid selected from His, Phe, Ala, Arg, Lys, Orn, Trp, Nap, Tpi and Tic, on the condition that at least one of AA1, AA2 or AA3 represent Phe, preferably Dphe in the form of enantiomers or diastereoisomers and mixtures thereof, including racemic mixtures.Type: GrantFiled: May 10, 2005Date of Patent: September 13, 2011Assignees: Centre National de la Recherche Scientifique (CNRS), Institut Europeen de Biologie Cellulaire, Universite de Montpellier I, Universite Montpellier IIInventors: Jean Martinez, Pascal Verdie, Pascaline Dubs, Anne-Marie Pinel, Gilles Subra
-
Publication number: 20110195922Abstract: This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2?-deoxy-?-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2?-deoxy-?-L-erythro-pentofuranonucleoside has the formula: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2?-deoxy-?-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2?-deoxy-?-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.Type: ApplicationFiled: December 8, 2009Publication date: August 11, 2011Applicants: Idenix Pharmaceuticals, Inc., Centre National de la Recherche Scientifique, L'Universite Montpellier IIInventors: Gilles Gosselin, Jean-Louis Imbach, Martin L. Bryant
-
Patent number: 7989467Abstract: The invention relates to indole-derived compounds and to the use of said compounds for the preparation of a medicament that can be used to treat diseases related to the process of splicing pre-messenger RNAs in the cell, such as Frasier syndrome, frontotemporal dementia linked to chromosome 17 (a form of Parkinson's disease), Leigh syndrome (a type of encephalopathy), atypical cystic fibrosis, certain neuropathologies including Alzheimer's disease linked to a mutation in the Tau protein, muscle atorphy which affects the SMN (Survival of Motor Neuron) gene, depression linked to a serotonin splicing impairment, and certain cancers in which the global splicing process is affected (e.g. breast cancer, colon cancer and certain lymphomas), as well as viral diseases such as AIDS.Type: GrantFiled: September 6, 2004Date of Patent: August 2, 2011Assignees: Centre National de la Recherche Scientifique (CNRS), Universite Montpellier II, Institut CurieInventors: Jamal Tazi, Johann Soret, Philippe Jeanteur, David Grierson, Christian Rivalle, Emile Bisagni, Chi Hung Nguyen
-
Publication number: 20110160254Abstract: The present invention relates to a combination of antimalarial active ingredients, namely a bisthiazolium salt or a precursor thereof and artemisinin or derivatives thereof. The invention also relates to a pharmaceutical composition comprising such a combination and use thereof in the treatment and/or prevention of malaria.Type: ApplicationFiled: August 6, 2010Publication date: June 30, 2011Applicants: SANOFI-AVENTIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQU (CNRS), UNIVERSITE MONTPELLIER IIInventors: Laurent FRAISSE, Henri VIAL, Sharon Aurore WEIN
-
Patent number: 7951789Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV and/or HBV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.Type: GrantFiled: December 27, 2007Date of Patent: May 31, 2011Assignees: Idenix Pharmaceuticals, Inc., L'Université Montpellier IIInventors: Jean-Pierre Sommadossi, Gilles Gosselin, Claire Pierra, Christian Perigaud, Suzanne Peyrottes
-
Patent number: 7902202Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV and/or HBV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.Type: GrantFiled: April 25, 2008Date of Patent: March 8, 2011Assignees: Idenix Pharmaceuticals, Inc., L'Université Montpellier IIInventors: Jean-Pierre Sommadossi, Gilles Gosselin, Claire Pierra, Christian Perigaud, Suzanne Peyrottes
-
Patent number: 7847535Abstract: The invention relates to a method for supply to a magnetic coupler comprising several pairs of windings, each pair being formed from a first and a second adjacent paired winding, magnetically coupled to each other by means of a core of magnetic material. The method further consists of supplying the first winding of each pair with a supply voltage or current out of phase by an angle a with relation to the supply voltage or current for the second winding of the same pair. The absolute value of the angle a is greater than or equal to 4p/N for at least one pair of windings.Type: GrantFiled: July 4, 2006Date of Patent: December 7, 2010Assignees: Centre National de la Recherche Scientifique (C.N.R.S.), Institut National Polytechnique de Toulouse, Universite Montpellier IIInventors: Thierry Antoine Meynard, Francois Forest, Frederic Richardeau, Eric Laboure
-
Publication number: 20100249425Abstract: The invention relates to a process for modifying an inorganic substrate, directed toward giving it antimicrobial properties, said process consisting in grafting in one or more steps onto a surface of said substrate groups with intrinsic antimicrobial properties or groups capable of releasing species with antimicrobial properties. The grafting is performed by means of an organophosphorus coupling agent. A subject of the invention is similarly a substrate obtained by this process, as well as diverse uses of such a substrate.Type: ApplicationFiled: December 21, 2006Publication date: September 30, 2010Applicants: Centre National De La Recherche Scientifique, Universite Montpellier II Sciences Et Techniques Du LanguedocInventors: Hubert Mutin, Gilles Guerrero, Julien Almaric
-
Patent number: 7794884Abstract: An active material for high-voltage negative electrodes (>1V vs. Li) of secondary rechargeable lithium batteries is disclosed. Chemical composition is represented by the general formula Li2+vTi3?WFeXMyM?ZO7??, where M and M? are metal ions having an ionic radius between 0.5 and 0.8 A and forming an octahedral structure with oxygen, like Ti3+, Co2+, Co3+, Ni2+, Ni3+, Cu2+, Mg2+, Al3+, In3+, Sn4+, Sb3+, Sb5+, ? is related to the formal oxidation numbers n and n? of M and M? by the relation 2?=v+4w?3x?ny?n?z and the ranges of values are ?0.5?V?0.5, 0?w?0.2, x>0, y+z>0 and x+y+z?0.7. The structure is related to that of ramsdellite for all the compositions. The negative active material is prepared by ceramics process wherein lithium oxide, titanium oxide, iron oxide, M and/or M? oxide are used as starting material for synthesis. Inorganic or organic solid precursors of the oxides can also be used instead. After reactant dispersion the mixture is fired.Type: GrantFiled: April 26, 2004Date of Patent: September 14, 2010Assignees: Umicore, Universite Montpellier IIInventors: Jean-Claude Jumas, Josette Olivier-Fourcade, Pierre-Emmanuel Lippens, Laurent Aldon, Aurélie Picard, Pierre Kubiak
-
Patent number: 7795238Abstract: This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2?-deoxy-?-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2?-deoxy-?-L-erythro-pentofuranonucleoside has the formula: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2?-deoxy-?-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2?-deoxy-?-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.Type: GrantFiled: October 30, 2007Date of Patent: September 14, 2010Assignees: Idenix Pharmaceuticals, Inc., Centre National de la Recherche Scientifique, L'Université Montpellier IIInventors: Gilles Gosselin, Jean-Louis Imbach, Martin L. Bryant
-
Publication number: 20100204184Abstract: The invention concerns novel phosphonate derivatives, preparation method, use thereof as ligands modulating T ?9?2 lymphocyte activity and pharmaceutical compositions comprising them.Type: ApplicationFiled: January 14, 2010Publication date: August 12, 2010Applicants: LABORATOIRES MAYOLY SPINDLER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE MONTPELLIER IIInventors: Jean-Louis Montero, Ibrahim Zgani, Chantal Menut, Valérie Gallois
-
Publication number: 20100152126Abstract: This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2?-deoxy-?-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2?-deoxy-?-L-erythro-pentofuranonucleoside has the formula: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2?-deoxy-?-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2?-deoxy-?-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.Type: ApplicationFiled: December 8, 2009Publication date: June 17, 2010Applicants: Idenix Pharmaceuticals, Inc., Centre National de la Recherche Scientifique, L'Universite Montpellier IIInventors: Gilles Gosselin, Jean-Louis Imbach, Martin L. Bryant
-
Patent number: 7696533Abstract: The invention relates to a structure usable in electronic, optical or optoelectronic engineering which comprises a substantially crystalline layer made of an alloy consisting of at least one element of the column II of the periodic elements system and/or at least one element of the column IV of the periodic elements system and of N2 (said alloy being noted N-IV-N2), wherein said structure also comprises an InN layer. A method for producing an indium nitride layer, a substrate forming plate and the use thereof for indium nitride growth are also disclosed.Type: GrantFiled: September 14, 2005Date of Patent: April 13, 2010Assignees: Centre National de la Recherche Scientifique (CNRS), Universite Montpellier IIInventors: Bernard Gil, Olivier Gérard Serge Briot, Sandra Ruffenach, Bénédicte Maleyre, Thierry Joseph Roland Cloitre, Roger-Louis Aulombard
-
Publication number: 20100056448Abstract: The invention relates to the use of the ubiquitous vertebrate glucose transporter GLUT1, or of fragments or sequences derived thereof, for the in vitro diagnosis of cancers, when used as a tumor marker, or for the screening of compounds useful for the preparation of drugs for the prevention or the treatment of pathologies linked to an infection of an individual with a PTLV, or pathologies linked to an overexpression of GLUT1 on cell surfaces, or the in vitro detection of GLUT1 on cell surfaces. The invention also relates to pharmaceutical compositions containing GLUT1, or fragments or sequences derived thereof, and to their uses such as in the frame of the prevention or the treatment of pathologies linked to an infection of an individual with a PTLV.Type: ApplicationFiled: August 26, 2009Publication date: March 4, 2010Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE UNIVERSITE MONTPELLIER IIInventors: Jean-Luc Georges Laurent BATTINI, Nicolas Gabriel Albert Manel, Felix Jinhyun Kim, Sandrina Kinet, Naomi Taylor, Marc Sitbon
-
Patent number: 7662798Abstract: 2? and 3?-Prodrugs of 1?, 2?, 3? or 4?-branched ?-D or ?-L nucleosides, or their pharmaceutically acceptable salts and derivatives are described, which are useful in the prevention and treatment of Flaviviridae infections and other related conditions. These modified nucleosides provide superior results against flaviviruses and pestiviruses, including hepatitis C virus and viruses generally that replicate through an RNA dependent RNA reverse transcriptase. Compounds, compositions, methods and uses are provided for the treatment of Flaviviridae infection, including HCV infection, that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.Type: GrantFiled: June 27, 2003Date of Patent: February 16, 2010Assignees: Idenix Pharmaceuticals, Inc., University of Cagliari, Centre National de la Recherche Scientifique, L'Universite Montpellier IIInventors: Paola LaColla, Jean-Pierre Sommadossi, Gilles Gosselin
-
Patent number: 7642061Abstract: The invention relates to the use of the ubiquitous vertebrate glucose transporter GLUT1, or of fragments or sequences derived thereof, for the in vitro diagnosis of cancers, when used as a tumor marker, or for the screening of compounds useful for the preparation of drugs for the prevention or the treatment of pathologies linked to an infection of an individual with a PTLV, or pathologies linked to an overexpression of GLUT1 on cell surfaces, or the in vitro detection of GLUT1 on cell surfaces. The invention also relates to pharmaceutical compositions containing GLUT1, or fragments or sequences derived thereof, and to their uses such as in the frame of the prevention or the treatment of pathologies linked to an infection of an individual with a PTLV.Type: GrantFiled: April 30, 2004Date of Patent: January 5, 2010Assignees: Centre National de la Recherche Scientifique, Universite Montpellier IIInventors: Jean-Luc Georges Laurent Battini, Nicolas Gabriel Albert Manel, Felix Jinhyun Kim, Sandrina Kinet, Naomi Taylor, Marc Sitbon
-
Patent number: 7635689Abstract: 2? and/or 3? prodrugs of 1?, 2?, 3? or 4?-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.Type: GrantFiled: December 6, 2004Date of Patent: December 22, 2009Assignees: Idenix Pharmaceuticals, Inc., Universita Degli Studi di Cagliari, Centre National de la Recherche Scientifique, L'Universite Montpellier IIInventors: Paola LaColla, Richard Storer, Gilles Gosselin, Jean-Pierre Sommadossi
-
Patent number: 7625875Abstract: 2? and 3?-Prodrugs of 1?, 2?, 3? or 4?-branched ?-D or ?-L nucleosides, or their pharmaceutically acceptable salts and derivatives are described, which are useful in the prevention and treatment of Flaviviridae infections and other related conditions. These modified nucleosides provide superior results against flaviviruses and pestiviruses, including hepatitis C virus and viruses generally that replicate through an RNA dependent RNA reverse transcriptase. Compounds, compositions, methods and uses are provided for the treatment of Flaviviridae infection, including HCV infection, that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.Type: GrantFiled: December 6, 2004Date of Patent: December 1, 2009Assignees: Idenix Pharmaceuticals, Inc., Universita Degli Studi di Cagliari, Centre National de la Recherche Scientifique, L'Universite Montpellier IIInventors: Gilles Gosselin, Richard Storer, Paola LaColla, Jean-Pierre Sommadossi